Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19

Andrea Mazzanti, Martina Briani, Deni Kukavica, Francesca Bulian, Stefano Marelli, Alessandro Trancuccio, Nicola Monteforte, Tommaso Manciulli, Massimo Morini, Annalisa Carlucci, Giacomo Viggiani, Francesco Cannata, Sara Negri, Raffaella Bloise, Mirella Memmi, Patrick Gambelli, Andrea Carbone, Martina Molteni, Raffaella Bianchini, Rita SalgarelloSilvia Sozzi, Pasquale De Cata, Francesco Fanfulla, Piero Ceriana, Carlo Locatelli, Carlo Napolitano, Luca Chiovato, Luca Tomasi, Giulio G. Stefanini, Gianluigi Condorelli, Silvia G. Priori

Research output: Contribution to journalLetterpeer-review

Abstract

Hydroxychloroquine is currently prescribed in many countries as a treatment for patients with coronavirus disease 2019 (COVID-19). The notion that hydroxychloroquine blocks the hERG (human ether-a-go-go-related gene) potassium channel, potentially leading to QT interval prolongation and arrhythmias, mitigates the enthusiasm for the compound. Recent studies conducted on cohorts of COVID-19 patients treated with hydroxychloroquine reported different signals, ranging from serious concern related to 20% of patients with major corrected QT (QTc) interval prolongation,1 to more reassuring data.2
Original languageEnglish
Pages (from-to)513-515
Number of pages3
JournalCirculation
Volume142
Issue number5
DOIs
Publication statusPublished - Aug 4 2020

Keywords

  • arrhythmia
  • COVID-19
  • hydroxychloroquine
  • long QT syndrome

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19'. Together they form a unique fingerprint.

Cite this